Articles tagged with: Pomalidomide
One of the advantages of living in the U.S. northeast is the chance to experience the change of the seasons. This year, the arrival of spring coincided with a new medical regimen for me and what has seemed like a rebirth of my own life.
As I described in my April column, this past winter was the season of my discontent. In less than three months, I experienced two bouts of pneumonia. I was at the hospital at least once a week, and I had near constant gastric distress. …
The American Society of Clinical Oncology will hold its 49th annual meeting May 31 through June 4 in Chicago.
Similar to previous years, more than 25,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. The theme for this year’s meeting is “Building Bridges to Conquer Cancer.”
During a session at the International Myeloma Workshop (IMW) held in Japan last week, Dr. Keith Stewart from the Mayo Clinic summarized the latest findings from research related to the protein cereblon and its impact on certain myeloma treatments.
Dr. Stewart reported that low levels of cereblon are associated with lower response rates and reduced survival outcomes in multiple myeloma patients treated with the immunomodulatory agents Revlimid (lenalidomide), thalidomide (Thalomid), and Pomalyst (pomalidomide).
He explained that, with further investigation, these findings may eventually help physicians …
A sub-analysis of recent Phase 2 clinical trial results indicates that Pomalyst in combination with low-dose dexamethasone is effective and safe in multiple myeloma patients with high-risk chromosomal abnormalities who did not respond to prior therapy.
The findings were presented by Dr. Paul Richardson of the Dana-Farber Cancer Institute in Boston at the International Myeloma Workshop (IMW) in Kyoto, Japan, this past Sunday.
In the new analysis, high-risk patients were defined as those with a deletion in chromosome 17 (del17p) or the translocation t(4;14).
Although the response rates were lower and survival …
Looking back at all that has happened in the world of multiple myeloma since January of 2012, it is hard not to be impressed by the many important developments that took place.
There is the obvious fact that, during that time, not one, but two new drugs to treat myeloma were approved by the U.S. Food and Drug Administration (FDA). Prior to 2012, the FDA had not approved a novel anti-myeloma therapy in over six years.
Yet 2012 was meaningful to the myeloma community for reasons beyond the activity at …